246.11
-5.30 (-2.11%)
| Previous Close | 251.41 |
| Volume | 294,686 |
| Price / Earnings (Forward) | 16.28 |
| Price / Sales | 3.66 |
| Price / Book | 1.98 |
| 52 Weeks Range |
| Profit Margin | 15.07% |
| Operating Margin (TTM) | 28.05% |
| Diluted EPS (TTM) | 10.12 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Quarterly Earnings Growth (YOY) | -38.90% |
| Total Debt/Equity (MRQ) | 39.00% |
| Current Ratio (MRQ) | 1.44 |
| Operating Cash Flow (TTM) | 2.58 B |
| Levered Free Cash Flow (TTM) | 3.43 B |
| Return on Assets (TTM) | 5.43% |
| Return on Equity (TTM) | 9.19% |
News Mood
-
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
3 days ago, 9:16AM
-
What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
3 days ago, 9:29PM
-
Biogen (BIIB) Stock May Be 49% Undervalued After Fresh Alzheimer’s Data
3 days ago, 8:14AM
-
Should Biogen Stock Holders Look At Amgen Instead?
2 days ago, 5:30AM
AIStockmoo Score
| Value 30% | -2.4 |
| Dearer than its usual valuation. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Low debt. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 3.8 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.5 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 1.1 |
| Institutions net +0.95% of shares in their latest 13F filings: 549 holders increased, 440 decreased (quarter to 30 Sep 2026). info | |
| Short interest -4.8% from 31 Aug to 30 Oct 2026, 4 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Earnings per share have mostly fallen. Earnings have been uneven. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. info | |
| Short-term momentum fading. info | |
| Price is near support. Levels trending up. info | |
| Final Score | 0.68 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Biogen Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| BIIB | - | - | - | 1.98 | 0.7 |
| GRFS | - | 1.08% | - | 0.900 | 1.1 |
| SNY | 112 B | 5.21% | 23.14 | 1.37 | 0.3 |
| AMGN | 236 B | 2.28% | 25.25 | 16.73 | 1.0 |
| GILD | 206 B | 1.95% | - | 16.08 | 0.6 |
| MIRA | 15 M | - | 36.83 | 3.72 | -1.0 |
Select this tab to load the latest available analysis.
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 92.79% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 116.68%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 549 | 10,525,966 |
| Decreased | 440 | 9,615,344 |
| New | 113 | 1,651,262 |
| Sold out | 80 | 1,158,196 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 5,453,103 | 4.0 |
| 15 Oct 2026 | 5,500,386 | 4.4 |
| 30 Sep 2026 | 5,965,892 | 4.9 |
| 15 Sep 2026 | 5,817,797 | 7.6 |
| 31 Aug 2026 | 5,726,631 | 8.7 |
| 14 Aug 2026 | 5,190,555 | 6.1 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
Should Biogen Stock Holders Look At Amgen Instead?
Today's big story: Could Anthropic Stock Fall 25… |
| 19 Nov 2026 | Yahoo Finance |
Biogen reports two-year Phase II data for diranersen in Alzheimer’s
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's. |
| 18 Nov 2026 | Yahoo Finance |
What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
Biogen (NasdaqGS:BIIB) said it has entered a research collaboration with TRIMTECH Therapeutics to develop small molecule protein degraders for neurodegenerative diseases. The agreement focuses on discovering targeted degraders that aim to remove disease related proteins in conditions such as… |
| 18 Nov 2026 | Yahoo Finance |
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced new three-year real-world findings of 560 patients across 13 U.S. clinical sites from the largest analysis of the ongoing Lecanemab in Early Alzheimer's Disease (LEADER) study* reported to date. New LEADER findings from a pre-specified… |
| 18 Nov 2026 | Yahoo Finance |
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
Biogen (NasdaqGS:BIIB) reported positive two year Phase 2 CELIA results for diranersen in early Alzheimer’s disease. The firm released new five year data for lecanemab that showed sustained clinical benefit and reduced progression risk in treated patients. Management framed these late stage… |
| 18 Nov 2026 | Yahoo Finance |
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts. |
| 18 Nov 2026 | Yahoo Finance |
Biogen (BIIB) Stock May Be 49% Undervalued After Fresh Alzheimer’s Data
Biogen has had a strong run over the past year, helped by fresh Alzheimer’s data and new product formats. This puts the focus squarely on whether the current share price lines up with the cash the business can generate. With the stock now around US$250.79 at the last close, the key issue is how… |
| 18 Nov 2026 | Yahoo Finance |
Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
Biogen (BIIB) is back in the Alzheimer’s spotlight after new five year data for lecanemab and two year Phase 2 results for diranersen outlined sustained clinical benefits and supportive safety signals. Investors have been rewarding this stream of Alzheimer’s updates, with Biogen’s share price… |
| 17 Nov 2026 | Yahoo Finance |
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen (NASDAQ:BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference… |
| 17 Nov 2026 | Yahoo Finance |
Biogen: 3 Key Takeaways for Long-Term Investors
Late-stage trials could reshape the rare disease franchise, but the real story is whether the pipeline matters at all. |
| 17 Nov 2026 | Yahoo Finance |
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
CARLSBAD, Calif., November 17, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in… |
| 16 Nov 2026 | Yahoo Finance |
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril antibody, were presented at the 19th Clinical Trials on Alzheimer's… |
| 16 Nov 2026 | Yahoo Finance |
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
CAMBRIDGE, England, November 16, 2026--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and… |
| 12 Nov 2026 | Yahoo Finance |
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home AdministrationTOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name… |
| 10 Nov 2026 | Yahoo Finance |
Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs
Two neighbors get the same Alzheimer's diagnosis and the same prescription, yet only one can count on a manageable bill. A missed registry rule and a closed enrollment window could decide who pays, and the clock runs out December 7… |
| 09 Nov 2026 | Yahoo Finance |
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO data for the first time found greater proportions of patients receiving DZP plus… |
| 05 Nov 2026 | Yahoo Finance |
Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts
Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Health Care Fund”. The letter can be downloaded here. During the quarter ended September 30, 2026, Baron Health Care Fund® advanced 4.02%, underperforming the Russell 3000 Health Care Index’s 6.19%… |
| 05 Nov 2026 | Yahoo Finance |
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
TORONTO, November 05, 2026--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement… |
| 05 Nov 2026 | Yahoo Finance |
Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?
Biogen recently shared new clinical, biomarker and safety data on its Alzheimer’s portfolio at the CTAD 2026 conference, including extended Phase 2 CELIA results for diranersen and long term analyses for lecanemab. The breadth of readouts, from 96 week diranersen extension data to real world… |
| 02 Nov 2026 | Yahoo Finance |
Should You Buy The Dip In Alnylam Stock?
For questions about this article or underlying research, email [email protected]. |
| 30 Oct 2026 | Yahoo Finance |
What Just Happened To Alnylam Stock?
For questions about this article or underlying research, email [email protected]. |
| 29 Oct 2026 | Yahoo Finance |
Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not… |
| 29 Oct 2026 | Yahoo Finance |
Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls
Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls… |
| 29 Oct 2026 | Yahoo Finance |
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab presentations will highlight new long-term and real-world evidence, including initial five-year… |
| Show more | ||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |